Relmada Therapeutics (RLMD) Competitors $0.36 +0.01 (+2.89%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RLMD vs. XCUR, SNYR, ACAB, CDIO, ALRN, BIVI, VIRI, DYAI, ESLA, and ICCCShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Exicure (XCUR), Synergy CHC Corp. (Uplisting) (SNYR), Atlantic Coastal Acquisition Corp. II (ACAB), Cardio Diagnostics (CDIO), Aileron Therapeutics (ALRN), BioVie (BIVI), Virios Therapeutics (VIRI), Dyadic International (DYAI), Estrella Immunopharma (ESLA), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Exicure Synergy CHC Corp. (Uplisting) Atlantic Coastal Acquisition Corp. II Cardio Diagnostics Aileron Therapeutics BioVie Virios Therapeutics Dyadic International Estrella Immunopharma ImmuCell Relmada Therapeutics (NASDAQ:RLMD) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment. Do insiders & institutionals have more ownership in RLMD or XCUR? 45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 18.0% of Relmada Therapeutics shares are held by insiders. Comparatively, 8.4% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor RLMD or XCUR? In the previous week, Exicure had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 3 mentions for Exicure and 0 mentions for Relmada Therapeutics. Exicure's average media sentiment score of 0.30 beat Relmada Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the news media. Company Overall Sentiment Relmada Therapeutics Neutral Exicure Neutral Which has more risk and volatility, RLMD or XCUR? Relmada Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.66, indicating that its share price is 266% more volatile than the S&P 500. Does the MarketBeat Community favor RLMD or XCUR? Relmada Therapeutics received 8 more outperform votes than Exicure when rated by MarketBeat users. However, 47.37% of users gave Exicure an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformRelmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% ExicureOutperform Votes947.37% Underperform Votes1052.63% Is RLMD or XCUR more profitable? Relmada Therapeutics' return on equity of -129.80% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -129.80% -112.06% Exicure N/A -190.90%-36.75% Which has preferable earnings and valuation, RLMD or XCUR? Exicure has higher revenue and earnings than Relmada Therapeutics. Exicure is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$98.79M-$2.87-0.13Exicure$500K97.31-$16.91M-$2.07-9.02 Do analysts rate RLMD or XCUR? Relmada Therapeutics presently has a consensus target price of $4.25, indicating a potential upside of 1,071.12%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relmada Therapeutics is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRelmada Therapeutics and Exicure tied by winning 8 of the 16 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.95M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.1310.5991.3417.19Price / SalesN/A195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.135.104.794.78Net Income-$98.79M$151.51M$120.07M$225.60M7 Day Performance-1.12%-2.15%-1.89%-1.24%1 Month Performance-86.80%-3.14%11.45%3.36%1 Year Performance-87.70%11.50%30.61%16.58% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.1808 of 5 stars$0.36+2.9%$4.25+1,071.1%-85.2%$10.95MN/A-0.1310Gap DownXCURExicure0.8904 of 5 stars$18.35+6.0%N/A+2,901.6%$47.89M$28.83M-9.2750News CoverageGap UpSNYRSynergy CHC Corp. (Uplisting)N/A$5.50+4.4%N/AN/A$47.85MN/A0.0040Positive NewsGap UpACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.7%$47.14MN/A0.004High Trading VolumeCDIOCardio Diagnostics2.6566 of 5 stars$1.16-7.9%$2.00+72.4%-55.7%$46.91M$35,688.000.007Gap UpHigh Trading VolumeALRNAileron Therapeutics3.0723 of 5 stars$2.16-4.4%$19.00+779.6%-43.5%$46.81MN/A-0.729Positive NewsBIVIBioVie1.1623 of 5 stars$2.62-0.8%$3.00+14.5%+47.3%$46.55MN/A-0.2310VIRIVirios TherapeuticsN/A$2.36-2.1%$3.00+27.1%+287.1%$45.45MN/A-8.745DYAIDyadic International1.6371 of 5 stars$1.51-7.4%$6.00+297.4%+12.2%$44.68M$3.36M-7.097Gap DownESLAEstrella Immunopharma0.1501 of 5 stars$1.21+1.6%N/A-7.2%$43.87MN/A-4.50N/AGap DownICCCImmuCellN/A$4.90-0.4%N/A-7.9%$43.67M$23.84M-9.8475Positive NewsGap Down Related Companies and Tools Related Companies Exicure Alternatives Synergy CHC Corp. (Uplisting) Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Cardio Diagnostics Alternatives Aileron Therapeutics Alternatives BioVie Alternatives Virios Therapeutics Alternatives Dyadic International Alternatives Estrella Immunopharma Alternatives ImmuCell Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLMD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts